Physician profile
Bruce D Bauer
NPI 1326363292
$14,325.69
in general payments reported to CMS, 2019-2025
36 companies · $2,417 in 2025
The $2,417 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,879 · 2020: $1,102 · 2021: $1,125 · 2022: $1,732 · 2023: $2,639 · 2024: $3,431 · 2025: $2,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,528 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $873 · Education: $85.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,528.39 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $872.82 |
| Education | $85.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,724.59 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Amgen INC. | $1,078.43 | 2019-2025 | Otezla, Enbrel, Otezla |
| Ucb, INC. | $1,032.20 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $992.48 | 2019-2025 | Tremfya, Simponi, Stelara |
| Novartis Pharmaceuticals Corporation | $853.20 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $677.52 | 2020-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $655.17 | 2019-2024 | Olumiant, Taltz |
| Sun Pharmaceutical Industries INC. | $493.12 | 2019-2025 | Winlevi, Absorica Ld, Odomzo |
| Pfizer INC. | $453.29 | 2019-2025 | |
| Leo Pharma INC. | $433.57 | 2019-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $425.75 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $403.48 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $364.77 | 2023-2025 | Zoryve |
| Incyte Corporation | $343.91 | 2021-2025 | Opzelura |
| Biofrontera INC. | $228.39 | 2020-2024 | Xepi, Bf-Rhodoled, Ameluz |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $201.38 | 2019-2025 | Nemluvio |
| Genentech USA, INC. | $141.66 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $129.71 | 2019 | |
| Dermira, INC. | $108.91 | 2020 | |
| Vyne Pharmaceuticals INC. | $102.25 | 2020-2021 | |
| Organon LLC | $65.82 | 2025 | Vtama |
| Epi Health, LLC | $55.16 | 2020-2022 | |
| Dermavant Sciences, INC. | $53.51 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.03 | 2022 | |
| Strata Skin Sciences, INC. | $38.53 | 2019 | |
| Mylan Institutional INC. | $38.38 | 2023 | Hulio |
| Verrica Pharmaceuticals INC. | $28.06 | 2023 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.05 | 2019 | |
| Revance Therapeutics, INC. | $21.78 | 2024 | Daxxify |
| Almirall LLC | $20.93 | 2019 | |
| Dusa Pharmaceuticals, INC. | $18.24 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $16.80 | 2020 | |
| Celgene Corporation | $16.07 | 2019 | |
| Stryker Corporation | $12.70 | 2019 | |
| Fresenius Kabi USA, LLC | $12.69 | 2023 | Idacio |
| Fidia Pharma USA INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Bauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.